Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP
J Pain Symptom Manage 2003;25(6):512-518.
Review by
The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study.
Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH
Laryngoscope 2002;112(7):1221-1229.
Review by Henry DH
Recombinant human erythropoietin in pediatric oncology: a review.
Feusner J, Hastings C
Med Pediatr Oncol 2002;39(4):463-468.
Review by Ford PA
The clinical value of erythropoietin in patients with cancer.
Duhrsen U
Drugs 2002;62(14):2013-2023.
Review by
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
Rizzo JD, Lichtin AE, Woolf SH, et al.
Blood 2002;100(7):2303-2320.
Review by
Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH, Chang CC, Chiang SS
Clin Nephrol 2002;57(2):136-141.
Review by Gasche C
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659